Cargando…
Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer
Ovarian cancer (OC) is estimated to kill ~14,000 women in the United States in 2019. Current chemotherapies to treat OC initially show therapeutic efficacy but frequently drug resistance develops, at which point therapies with alternative targets are needed. Herein, we are describing a novel approac...
Autores principales: | Lu, Tiangong, Tang, Jianming, Shrestha, Binita, Heath, Blake R., Hong, Li, Lei, Yu L., Ljungman, Mats, Neamati, Nouri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295058/ https://www.ncbi.nlm.nih.gov/pubmed/32550915 http://dx.doi.org/10.7150/thno.41792 |
Ejemplares similares
-
Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3
por: Lu, Tiangong, et al.
Publicado: (2019) -
Natural antisense transcript of hypoxia-inducible factor 1 regulates hypoxic cell apoptosis in epithelial ovarian cancer
por: Qiu, Jun-jun, et al.
Publicado: (2018) -
Current Challenges and Opportunities in Treating Glioblastoma
por: Shergalis, Andrea, et al.
Publicado: (2018) -
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010) -
Mechanistic Evaluation of a Novel Small Molecule Targeting Mitochondria in Pancreatic Cancer Cells
por: Shabaik, Yumna H., et al.
Publicado: (2013)